GSK - MarketMinute

GSK

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion. The deal, confirmed on January 20, 2026, represents a significant escalation in the multi-billion dollar race to dominate the

FTSE 100

FTSE 100 Soars to Record High, Fueled by Pharmaceutical Boom and Resilient Pound

London, UK – October 1, 2025 – The UK's benchmark FTSE 100 index has achieved an unprecedented milestone today, surging to a new all-time high. The robust performance was largely propelled by a significant rally in pharmaceutical stocks, alongside a strengthening British Pound, signaling renewed investor confidence in the UK

Pharmaceuticals

Healthcare Heavyweights Drive London's Blue-Chip Index to Unprecedented Levels

London's financial markets are buzzing today, October 1, 2025, as a robust rally in the pharmaceuticals sector has propelled the FTSE 100 to a new record high. This significant surge, primarily fueled by a landmark development in US drug pricing policy, underscores the critical influence of healthcare giants